Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response?

• Published in: International archives of allergy and immunology Vol. 164; no. 3; p. 237
• Main Authors: Kepil Özdemir, Seçil, Sin, Betül Ayşe, Güloğlu, Deniz, İkincioğulları, Aydan, Gençtürk, Zeynep, Mısırlıgil, Zeynep
• Format: Journal Article
• Language: English
• Published: Switzerland 01-01-2014
• Subjects: Adult; Allergens - immunology; Antigens, Plant - therapeutic use; Basophils - immunology; Desensitization, Immunologic - methods; Double-Blind Method; Female; Humans; Immunoglobulin E - blood; Immunoglobulin G - blood; Male; Phleum - immunology; Phosphoric Diester Hydrolases - biosynthesis; Phosphoric Diester Hydrolases - immunology; Placebos; Plant Extracts - therapeutic use; Pollen - immunology; Pyrophosphatases - biosynthesis; Pyrophosphatases - immunology; Rhinitis, Allergic, Seasonal - immunology; Rhinitis, Allergic, Seasonal - therapy
• ISSN: 1423-0097
• DOI: 10.1159/000365628

An aluminum hydroxide-adsorbed depot allergoid preparation of six-grass pollen allergens has been developed for short-term preseasonal immunotherapy in pollinosis. However, only limited knowledge exists about its immunological and clinical effects. The aim of this study was to evaluate the basophil response, which can explain early clinical findings of short-term preseasonal allergoid immunotherapy in allergic rhinitis.
In a double-blind, placebo-controlled study, 31 patients allergic to grass pollens received one course of short-term preseasonal allergoid immunotherapy or placebo. Immunogenicity was assessed by the levels of specific IgG4, IgE antibodies and an allergen-induced CD203c basophil activation test. The primary clinical end point was the combined symptom and medication score/average combined score (ACS).
There was a 52.9% difference in ACS between the treatment and placebo groups in favor of immunotherapy (p = 0.01). Active treatment induced Phleum pratense-specific IgG4 and IgE antibodies (p < 0.05). A decrease in allergen-induced basophil activation at submaximal allergen concentrations was demonstrated at the end of immunotherapy and at the peak of the grass pollen season after immunotherapy.
This study shows that grass pollen-allergic patients treated with one course of short-term preseasonal allergoid immunotherapy exhibit a decrease in allergen-induced basophil activation, an increase in allergen-specific IgG4 antibodies and early clinical improvement.